Huixin Lifetech key facts
as of Oct 2026- Developer of technology and diagnostic products in the field of liquid biopsy.
- Huixin Lifetech is valued at approximately $135.9M as of Oct 2026 (last reported valuation).
- It has raised $29.5M; the latest was Later Stage VC ($14.2M) in Jan 2026.
- Notable investors include Legend Capital, Co-Win Ventures, South China Venture Capital, Green River Investment, HaoYue Capital — 7 tracked in total.
- Status: Privately Held (backing).
Huixin Lifetech's last reported valuation, Jan 2026. Nothing priced has surfaced since.
- ·Watch Huixin Lifetech: the Monday email on marks, rounds and moves
Huixin Lifetech funding rounds
No funding rounds for Huixin Lifetech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Huixin Lifetech valuation
Huixin Lifetech's last reported valuation was $136 million in Jan 2026. No priced round, secondary trade or fund mark has surfaced since.
Huixin Lifetech investors
7 investors are on record for Huixin Lifetech, including Legend Capital, Co-Win Ventures, South China Venture Capital and Green River Investment.
About Huixin Lifetech
Developer of technology and diagnostic products in the field of liquid biopsy. The company offers research and development and application of exosomes in early diagnosis and treatment of diseases, especially combining exosomes with liquid biopsy techniques including various medical equipment, general laboratory reagents, and microfluidic chip, thereby enabling patients with solutions that could achieve early screening of cancer.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2017
- Website
- huixinbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.